Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature
Authors:
- Paul GrootendorstPGPaul Grootendorst
- Emmanuelle PiérardEPEmmanuelle Piérard
- Minsup ShimMSMinsup Shim
- 1 August 2009
- journal article
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 9 (4) , 353-364
Abstract
Several studies suggest that, on the basis of life-expectancy regressions, pharmaceutical drugs are responsible for much of the marked gains in life expectancy observed over the last 50 years. In this article, we critically appraise these studies. We point out several modeling issues: identification of the contribution of new drugs from advances in disease management, changes in the distribution of healthcare and other confounding factors. We suggest that some models produce estimates of pharmaceutical productivity that are implausibly high. Other models have very large forecast errors. Finally, the models that we replicated were found to be sensitive to seemingly innocuous changes in specification. It is difficult to estimate the biomedical determinants of life expectancy using aggregate data. Analyses using individual level data or perhaps disease-specific data will probably produce more compelling results.Keywords
All Related Versions
This publication has 17 references indexed in Scilit:
- Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country‐level data on 20 OECD countries, 1995–2003Health Economics, 2008
- Does health care spending improve health outcomes? Evidence from English programme budgeting dataJournal of Health Economics, 2008
- Advances In The Prevention And Treatment Of Cardiovascular DiseaseHealth Affairs, 2007
- The Determinants of MortalityJournal of Economic Perspectives, 2006
- The relationship between health care expenditure and health outcomesThe European Journal of Health Economics, 2006
- The Determinants of Life Expectancy: An Analysis of the OECD Health DataSouthern Economic Journal, 2005
- Public and private pharmaceutical spending as determinants of health outcomes in CanadaHealth Economics, 2004
- Physicians’ Views Of The Relative Importance Of Thirty Medical InnovationsHealth Affairs, 2001
- A Comparison of International Health Outcomes and Health Care SpendingInternational Journal of Technology Assessment in Health Care, 1994
- International cross-section analysis of the determination of mortalitySocial Science & Medicine, 1987